Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer

被引:0
|
作者
Carlos A. Huertas-Caro
Mayra A. Ramírez
Laura Rey-Vargas
Lina María Bejarano-Rivera
Diego Felipe Ballen
Marcela Nuñez
Juan Carlos Mejía
Luz Fernanda Sua-Villegas
Alicia Cock-Rada
Jovanny Zabaleta
Laura Fejerman
María Carolina Sanabria-Salas
Silvia J. Serrano-Gomez
机构
[1] National Cancer Institute of Colombia,Cancer Biology Research Group
[2] Pontificia Universidad Javeriana,Clinical Oncology Unit. Instituto Nacional de Cancerología and Adjunct Clinical Professor
[3] National Cancer Institute of Colombia,Research Support and Follow
[4] Instituto Nacional de Cancerología,Up Group
[5] Universidad ICESI,Grupo de Patología
[6] Instituto de Cancerología Las Américas,Department of Pathology and Laboratory Medicine, Fundación Valle del Lili, and Faculty of Health Sciences
[7] Louisiana State University Health Sciences Center,Department of Oncological Breast Surgery and Mastology
[8] University of California Davis,Department of Interdisciplinary Oncology and Stanley S. Scott Cancer Center
[9] University of California Davis,Department of Public Health Sciences
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Triple negative breast cancer (TNBC) is highly immunogenic and high levels of tumor infiltrating lymphocytes (TILs) have been associated with a better prognosis and higher probability to achieve pathological complete response. Here, we explore the potential role of stromal TILs level and composition as a prognostic and predictive biomarker in TNBC. 195 Tumor biospecimens from patients diagnosed with TNBC were included. Stromal TILs (sTILs), positive CD4/CD8 cells were evaluated. Differences in clinic-pathological characteristics according to immune infiltration were assessed. The predictive and prognostic value of immune infiltration was analyzed by multivariate models. Higher immune infiltration was observed in patients with favorable clinical–pathological features. Survival analysis showed that longer overall survival times were observed in patients with a higher infiltration of sTILs (p = 0.00043), CD4 + (p = 0.0074) and CD8 + (p = 0.008). In the multivariate analysis, low levels of sTILs were found to be associated with a higher mortality hazard (HR: 1.59, 95% CI 1.01–2.48). CD4 and CD8 immune infiltration were associated with higher odds for pathological complete response (OR: 1.20, 95% CI 1.00–1.46, OR: 1.28, 1.02–1.65, respectively). Our results suggest that immune infiltration could be used as a prognostic marker for overall survival in TNBC patients.
引用
收藏
相关论文
共 50 条
  • [31] Prognostic Assessment of Stromal and Non-Stromal Tumor-Infiltrating Lymphocytes (TILs) in Triple-Negative Breast Cancer (TNBC)
    Ghosh, Toshi
    Goetz, Matthew
    Leon-Ferre, Roberto A.
    Liu, Heshan
    Polley, Mei-Yin C.
    Ingle, James
    Cafourek, Victoria L.
    Hillman, David W.
    Carter, Jodi
    Visscher, Daniel
    MODERN PATHOLOGY, 2018, 31 : 61 - 62
  • [32] Tumor-infiltrating lymphocytes (TILs)/volume and prognosis: The value of TILs for survival in HER2 and TN breast cancer patients treated with chemotherapy
    Okcu, Oguzhan
    Ozturk, Seda Duman
    Ozturk, Cigdem
    Sen, Bayram
    Yasin, Ayse Irem
    Bedir, Recep
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2022, 58
  • [33] Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer
    Pruneri, G.
    Vingiani, A.
    Bagnardi, V.
    Rotmensz, N.
    De Rose, A.
    Palazzo, A.
    Colleoni, A. M.
    Goldhirsch, A.
    Viale, G.
    ANNALS OF ONCOLOGY, 2016, 27 (02) : 249 - 256
  • [34] Relevance of tumor infiltrating lymphocytes in patients with HER2 positive and triple negative breast cancer
    Denkert, C.
    BREAST, 2017, 32 : S12 - S12
  • [35] Tumor-infiltrating lymphocytes (TILs) is associated with improved overall survival in triple-negative breast cancer (TNBC) patients treated with neoadjuvant chemotherapy (NAC)
    Sampaio, Cd D. A. T.
    de Lima, V. C. C.
    de Andrade, V. P.
    Neotti, T.
    Tavares, M. C.
    Sessa, V. A.
    Calsavara, V. F.
    Zenun, G. R.
    Giongo, A. A.
    da Costa, A. A. B. A.
    CANCER RESEARCH, 2017, 77
  • [36] Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting
    Garcia-Teijido, Paula
    Luque Cabal, Maria
    Pelaez Fernandez, Ignacio
    Fernandez Perez, Yolanda
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2016, 10 : 31 - 39
  • [37] Clinical Significance of Stromal Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer
    Goel, Kanika
    Carter, Gloria
    Clark, Beth
    Fine, Jeffrey
    Yu, Jing
    Harinath, Lakshmi
    Villatoro, Tatiana
    Bhargava, Rohit
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 117 - 119
  • [38] Clinical Significance of Stromal Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer
    Goel, Kanika
    Carter, Gloria
    Clark, Beth
    Fine, Jeffrey
    Yu, Jing
    Harinath, Lakshmi
    Villatoro, Tatiana
    Bhargava, Rohit
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 117 - 119
  • [39] Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
    Si-Lin K.
    Kiley L.
    Kamis S.
    Iqbal J.
    Dent R.
    Sim Y.Y.
    Current Breast Cancer Reports, 2015, 7 (4) : 232 - 241
  • [40] Prognostic and predictive value of tumor-infiltrating lymphocytes in triple negative breast cancer
    Kim, E.
    Kwon, J.
    Byon, W.
    Song, B. J.
    Park, C.
    BREAST, 2015, 24 : S106 - S106